IGU can specifically disrupt Act1-TRAF5 and Act1-IKKi interactions without affecting Act1-TRAF6 binding35 in RA, which explains the inhibitory effect of IGU on the IL-17 pathway. Here, TRAF3IP2 is linked to rheumatoid arthritis.